Gathers detailed drug, drug-target, drug action and drug interaction information about drugs. DrugBank is a web resource that contains information about FDA-approved drugs as well as experimental drugs going through the FDA approval process. The database also includes pharmaco-omic data covering the influence of drugs on metabolite levels, gene expression levels and protein expression levels, as well as data on investigational drug clinical trials and drug repurposing trials, and thousands of up-to-date drug images of approved drugs.
A biobank of breast cancer explants with preserved intra-tumor heterogeneity to screen anticancer compounds. BCaPE provides tools for visualizing, querying and downloading data from a large collection of highly molecularly annotated breast cancer patient-derived tumour xenografts (PDTX). The biobank represents a powerful resource for pre-clinical breast cancer pharmacogenomic studies, including identification of biomarkers of response or resistance.
Compiles information relative to the prevalence of clinically relevant genomic variation allele frequency data in various populations and ethnic groups. FINDBase is divided into four main panels: (i) “causative mutations” census those frequencies engendering inherited disorders; (ii) “pharmacogenomic markers” displays those frequencies of pharmacogenetically relevant single nucleotide polymorphisms (SNPs); (iii) “ethnos databases” records information about described genetic heterogeneity by country; (iv) and “map” that allows users to visualize the third categories through an interactive map.
A relational database tool for storing, querying, integrating, and downloading molecular profile data on the NCI-60 and other cancer cell types. The newest CellMiner version includes integration of novel databases and tools associated with whole-exome sequencing and protein expression. Included are (i) "Cell line signature" for DNA, RNA, protein, and drugs; (ii) "Cross correlations" for up to 150 input genes, microRNAs, and compounds in a single query; (iii) "Pattern comparison" to identify connections among drugs, gene expression, genomic variants, microRNA, and protein expressions; (iv) "Genetic variation versus drug visualization" to identify potential new drug:gene DNA variant relationships; and (v) "Genetic variant summation" designed to provide a synopsis of mutational burden on any pathway or gene group for up to 150 genes. Together, these tools allow users to flexibly query the NCI-60 data for potential relationships between genomic, molecular, and pharmacologic parameters in a manner specific to the user's area of expertise.
Consists of Pharmacogenomics Research Network members, PharmGKB staff, and experts in pharmacogenetics, pharmacogenomics, and laboratory medicine. The CPIC provides a database of guidelines, a list of Genes and Drugs, a table of allele designed to help clinicians understand HOW available genetic test results should be used to optimize drug therapy, rather than WHETHER tests should be ordered. The methods proposed by CPIC have been endorsed by several professional societies.
Gathers information about in vitro drug screens. PharmacoDB compiles multiple publicly highthroughput cancer pharmacogenomic datasets to highlight drug or cell line of interest. The database supplies access to molecular profiles of cell lines and computational analytical tools via linkage to PharmacoGx, an R/Bioconductor package implementing a suite of statistical modeling functions to jointly analyze molecular features and drug dose-response curves.
Centralizes comprehensive information about genetic tests. GTR is a free online resource that organizes critical information such as the purpose of the test, target population, test methods, what the test measures, analytical validity, clinical validity, clinical utility, ordering information and test credentials as well as the laboratory name, location, contact information, certifications and licenses.
A comprehensive resource that curates knowledge about the impact of genetic variation on drug response for clinicians and researchers. PharmGKB has refocused on curating knowledge rather than housing primary genotype and phenotype data, and now, captures more complex relationships between genes, variants, drugs, diseases and pathways.
Contains a secure, de-identified, web-accessible repository of genomic variants. SPHINX is a resource for eMERGE-PGx. Sequence variants determined from PGRNseq on all enrolled eMERGE-PGx participants will be available to the public via SPHINX in aggregate forms. Due to the risk of possible patient re-identification using demographic and clinical data, this database includes important privacy safeguards.
Provides the target for many commonly used prescription drugs and is a major determinant of the absorption, distribution and elimination of many clinically used drugs. The Pharmacogenetics of Membrane Transporters provides a database that Identify sequence variants in coding and noncoding regions of genes encoding selected membrane transport proteins. It determines the biological relevance of genetic variants in membrane transporters to clinical drug disposition and response in ethnically diverse human populations. This project is part of the NIH sponsored Pharmacogenetics Research Network.
Offers access to drug-labeling data and facilitates their use in regulatory science, drug development, scientific research, and clinical application. FDALabel contains over 95 000 full-text Structured Product Labelings (SPLs) that include human prescription drugs and biological products, and human over-the-counter (OTC) drugs. Users can employ the database to get access to drug indications and warnings, as a pharmaceutical company for drug development, or as a researcher studying drug safety.
Gathers network pharmacology related interactions information at the systemic level. PhID aims to provides a repository for visualizing relationships between entities such as drugs, targets, diseases, genes, pathways, and side-effects. The database includes more than 306000 activities. Searches can be made by names, ids, molecular structures, or molecular fragments for different purposes.
Contains toxicity information for over 1.5 million genes from hundreds of microorganisms and exhibits the results of cloning attempts for each of these genes on single-copy and multiple-copy vectors within E. coli. PanDaTox allows to the researchers to avoid toxic genes and to select genes that were experimentally proven to be clonable within E. coli. Also, user can verify the clonability of selected genes before the actual metabolic engineering experiments are conducted.
Aims to gather various existing knowledge sources on pharmacogenomics (PGx). PGxLOD constitutes a community resource for PGx research where PGx relationships are associated to two levels of drug responses. It provides entities appearing as components of PGx relationships, as well as mappings between these entities. Moreover, this online resource can be improved with additional state of the art knowledges or with knowledges from electronic health records (EHR) mining.
Permits users to explore response of a panel of small cell lung carcinoma (SCLC) lines to Food and Drug Administration (FDA)-approved anticancer drugs. The SCLC database contains a library of investigational agents, along with exon and microRNA arrays. It stores a collection of screen data including the drug and compound data, and gene and miRNA expression data. The database provides an online interface and allows users to visualize or download data.
Provides a large-scale pharmacogenomics dataset to link disease-associated transcriptional signatures with chemical and genetic perturbagen-associated transcriptional signatures. Lincscloud is designed to make CMap/LINCS data accessible to a wide audience. It enables integrated analysis of CMap/LINCS datasets across all types of data emerging from L1000/LINCS assays, all types of users - computationalists, biologists, and software engineers, and all types of institutions - data generators, computational centers, non-consortium labs.
Lists food and drug administration (FDA)-approved drugs with pharmacogenomic information in their labeling. Pharmacogenomic Biomarkers in Drug Labeling provides a table of the drugs that includes specific actions to be taken based on the biomarker information. For drugs that are available in multiple dosage forms, salts, or combinations, a single representative product is listed. In the case of combination products, the single agent associated with the biomarker is listed unless the agent is only approved as a combination product, in which case all agents are listed. This table does not include non-human genetic biomarker.
Receives and stores polymorphic marker genotypes, copy number variant (CNVs) calls, and Sanger DNA sequences generated by users of the DNAs of the HGDP-CEPH Diversity Panel. HGDP-CEPH is a database which contains 1063 lymphoblastoid cell lines (LCLs) from 1050 individuals in 52 world populations and corresponding milligram quantities of DNA, in order to provide unlimited supplies of DNA and RNA for studies of sequence diversity and history of modern human populations. Information for each LCL is limited to sex of the individual, population and geographic origin.
Offers personalized recommendations based on pharmacogenomics evidence. ePGA is a web-based application that combines: (i) information retrieval on state of the art PGx variants, genes, drugs, and their associations, (ii) matching of individual genotype-profiles with PGx gene haplotypes and inference of corresponding diplotype profiles, accompanied by respective summary statistics, (iii) automated linkage of the inferred diplotypes with respective clinical annotations, recommendations and dosing guidelines and (iv) update services on newly discovered PGx variants and haplotypes.
Triangulates drugs with genes and pharmacogenomic biomarkers. The DruGeVar database enables the user to draw such useful conclusions from a large dataset not only by visualizing, sorting and categorizing data dynamically, but also by discovering trends across all display items and data records using different querying approaches. All DruGeVar database records depict drug/gene combinations that have been approved by any or both of the 2 major regulatory agencies, the FDA and the EMA.
Provides information about the effects of a particular protein polymorphism, non-coding region mutation, splicing alteration or expression variation on the response of a particular drug. PharmGED contains more than 1800 entries covering 100 disease conditions, 250 distinct proteins, about 700 polymorphisms, and 400 drugs/ligands. It aims to facilitate pharmacogenetic study and can be useful to predict various types of individual variations of drug responses.